Skip to main content

Table 1 Baseline demographic and clinicohistologic characteristics of the patients described in this study

From: Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer

Clinicohistologic feature

n (%)

Age, median [range]

60 [20–79]

 

Sex

Female

16 (22.5)

 

Male

54 (76.1)

 

Unknown

1 (1.4)

Stage

III

22 (31)

IV

48 (67.6)

Unknown

1 (1.4)

Histology

LUAD

56 (78.9)

LUSC

15 (21.1)

Smoking

Yes

33 (46.5)

No

38 (53.5)

Location of lung tumor

Central

39 (54.9)

Peripheral

28 (39.4)

Unknown

4 (5.6)

Sputum type

Induced

13 (18.3)

Non-induced

58 (81.7)

T stage

T1

9 (12.7)

 

T2

19 (26.8)

 

T3

15 (21.1)

 

T4

28 (39.4)

N stage

N0

1 (1.4)

 

N1

7 (9.9)

 

N2

22 (31)

 

N3

40 (56.3)

 

Unknown

1 (1.4)

M stage

M0

19 (26.8)

 

M1

48 (67.6)

 

Unknown

4 (5.6)

Nodal metastasis

Yes

68 (95.8)

No

2 (2.8)

Unknown

1 (1.4)

Brain metastasis

Yes

12 (16.9)

No

58 (81.7)

Unknown

1 (1.4)

Pleural metastasis

Yes

27 (38.0)

No

43 (60.6)

Unknown

1 (1.4)

Bone metastasis

Yes

12 (16.9)

No

58 (81.7)

Unknown

1 (1.4)

Tracheal violation

Yes

23 (32.4)

No

44 (62.0)

Unknown

4 (5.6)

Blood vessel invasion

Yes

12 (16.9)

No

56 (78.9)

Unknown

3 (4.2)

Pleurisy

Yes

19 (26.8)

No

48 (67.6)

Unknown

4 (5.6)

  1. LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma